Loading stock data…
$63.19-2.66 (-4.04%)
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
Celcuity Inc. in the Healthcare sector is trading at $63.19 with a market capitalization of $4.0B. Wall Street consensus targets $156.91 (11 analysts), implying a +148.3% move over the next 12 months. The stock is currently near its 52-week low of $46.51, remaining 38.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$66.12M↓ | -$50.51M↓ | -$49.20M↓ | -$42.85M↑ | -$44.01M |
| Net Income | -$78.86M↓ | -$52.84M↓ | -$50.97M↓ | -$43.80M↑ | -$45.27M |
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets ...